PDCD1 and neoplasm: After PD-1/Al@OV treatment, IL-1β and IL-6 levels were significantly reduced, while IFN-γ expression increased in tumor tissues, indicating that PD-1/Al@OV effectively enhanced the anti-tumor immune responses (Fig. 6J-L).